AQR Capital Management
AMRX icon

AQR Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

AQR Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7M Sell
864,792
-181,320
-17% -$2.43M ﹤0.01% 1307
2025
Q4 		$13.2M Buy
1,046,112
+32,096
+3% +$367K 0.01% 1091
2025
Q3 		$10.2M Sell
1,014,016
-5,089
-0.5% -$45.7K 0.01% 1086
2025
Q2 		$8.24M Buy
1,019,105
+273,630
+37% +$2.06M 0.01% 1050
2025
Q1 		$6.25M Buy
745,475
+408,677
+121% +$3.41M 0.01% 1041
2024
Q4 		$2.67M Buy
336,798
+33,545
+11% +$281K ﹤0.01% 1380
2024
Q3 		$2.52M Sell
303,253
-131,829
-30% -$1.03M ﹤0.01% 1383
2024
Q2 		$2.76M Sell
435,082
-321,305
-42% -$2.04M ﹤0.01% 1312
2024
Q1 		$4.58M Sell
756,387
-72,362
-9% -$408K 0.01% 1017
2023
Q4 		$5.03M Sell
828,749
-110,897
-12% -$494K 0.01% 948
2023
Q3 		$3.97M Sell
939,646
-1,216,596
-56% -$4.54M 0.01% 1018
2023
Q2 		$6.68M Sell
2,156,242
-854,660
-28% -$1.82M 0.01% 787
2023
Q1 		$4.19M Buy
3,010,902
+874,650
+41% +$1.74M 0.01% 971
2022
Q4 		$4.25M Buy
2,136,252
+1,164,091
+120% +$2.61M 0.01% 970
2022
Q3 		$1.96M Buy
972,161
+679,824
+233% +$1.91M ﹤0.01% 1209
2022
Q2 		$930K Buy
292,337
+55,339
+23% +$200K ﹤0.01% 1452
2022
Q1 		$988K Buy
+236,998
New +$1.05M ﹤0.01% 1540
2018
Q3 		– Sell
-41,041
Closed -$673K – 2258
2018
Q2 		$673K Buy
+41,041
New +$720K ﹤0.01% 1875

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management's AMRX Position: Q1 2026 in Review

AQR Capital Management reduced its Amneal Pharmaceuticals (AMRX) stake by 17% in Q1 2026, selling an estimated $2.43M and leaving 864,792 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1307.

AQR Capital Management first reported a position in AMRX in Q2 2018 and has held it in 18 quarters since. The position peaked at $13.2M in Q4 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • AQR Capital Management held 864,792 shares of Amneal Pharmaceuticals worth $10.7M as of Q1 2026.
  • AQR Capital Management sold 181,320 Amneal Pharmaceuticals shares in Q1 2026, an estimated $2.43M.
  • Amneal Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1307 holding.
  • AQR Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 18 quarters since.
  • AQR Capital Management's Amneal Pharmaceuticals position peaked at $13.2M in Q4 2025.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.